|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.95 USD | +5.58% |
|
+10.82% | +66.30% |
| Mar. 06 | Nektar Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) | RE |
| Mar. 03 | Intellia Therapeutics Presents Longer-Term Clinical Data For Lonvoguran Ziclumeran | CI |
Main competitors
| Change | 5d. change | 1 months change | 3 months change | Varia. Jan 1. | 1-year change | 3-years change | 5-years change | 10-years change | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
 | +5.58% | +10.82% | +10.91% | +19.60% | +66.30% | +106.78% | -61.91% | -78.78% | - | 1.77B | |
| +2.22% | +5.51% | +11.28% | -2.83% | +1.04% | +0.78% | -7.93% | -2.69% | +231.75% | 48.69B | |
| +0.99% | +4.59% | +12.72% | -4.23% | +6.60% | +40.22% | +22.31% | +6.00% | +914.63% | 35.92B | |
| -0.43% | +54.13% | +49.93% | +23.57% | +86.60% | +304.33% | +504.92% | +268.63% | - | 31.26B | |
| -0.72% | +3.91% | +0.73% | -0.72% | +14.64% | +35.55% | +29.11% | -21.96% | +159.91% | 29.77B | |
| +2.62% | +5.45% | +4.77% | -25.76% | -21.72% | +22.62% | -12.91% | -18.14% | +151.76% | 29.62B | |
| -6.22% | -0.52% | +24.81% | +4.52% | +36.52% | +3,641.35% | +3,836.02% | - | - | 14.18B | |
| +0.63% | +2.17% | +7.20% | +18.78% | +14.65% | +48.12% | +195.41% | +100.48% | +1,293.84% | 15.1B | |
| +0.96% | +5.48% | +14.38% | -14.78% | -7.31% | +75.71% | +166.26% | +189.38% | - | 14.87B | |
| +0.87% | +8.85% | +12.25% | -3.16% | +11.92% | +40.89% | +13.56% | -20.83% | +118.25% | 14.5B | |
| +0.60% | +0.72% | +4.67% | -0.81% | -4.30% | +166.58% | +100.40% | +85.65% | +78.23% | 12.51B | |
| +2.66% | +30.11% | +9.89% | -20.56% | -5.39% | +38.12% | - | - | - | 10.01B | |
| +1.45% | -2.97% | -4.47% | +2.45% | -13.04% | +1,898.09% | +893.36% | +432.01% | +849.23% | 9.79B | |
| +3.26% | +6.64% | +16.00% | -13.75% | +0.71% | +23.14% | -30.51% | -43.40% | +154.94% | 9.27B | |
| +6.90% | +8.34% | +12.89% | +7.96% | +16.20% | +913.61% | +2,054.09% | -16.58% | - | 9.54B | |
| +3.55% | +12.05% | +19.10% | -34.46% | -34.32% | -14.10% | -44.07% | -41.47% | +63.39% | 9.14B | |
| +3.92% | +4.69% | +19.63% | -16.30% | -7.82% | +73.39% | -11.83% | -43.14% | +128.51% | 9.07B | |
| +0.68% | +0.86% | -0.72% | -13.31% | -12.88% | -3.76% | -20.03% | -29.96% | +53.36% | 8.53B | |
| +0.14% | -.--% | -.--% | -.--% | -.--% | +52.86% | +168.20% | +35.99% | +582.09% | 8.38B | |
| -2.93% | -2.06% | +10.20% | -4.60% | +7.18% | +38.12% | -17.86% | -53.20% | - | 7.56B | |
| Average | +1.17% | +7.94% | +11.81% | -3.92% | +7.78% | +375.12% | +409.30% | +41.56% | +367.68% | 16.47B | |
| Weighted average by Cap. | +0.94% | +9.70% | +13.38% | -3.26% | +9.69% | +298.02% | +333.31% | +48.47% | +384.75% |
- Stock Market
- Equities
- NTLA Stock
- Sector Intellia Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
